Cargando…

Financial burden impact quality of life among lymphatic Filariasis patients

BACKGROUND: Human lymphatic filarial pathology is the leading cause of disability and poverty among people living with the infection. The second goal of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) is to manage the disease’s morbidity to improve patients’ quality of life. Consequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Asiedu, Samuel Opoku, Kwarteng, Alexander, Amewu, Emmanuel Kobla Atsu, Kini, Priscilla, Aglomasa, Bill Clinton, Forkuor, John Boulard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818560/
https://www.ncbi.nlm.nih.gov/pubmed/33478462
http://dx.doi.org/10.1186/s12889-021-10170-8
_version_ 1783638861033766912
author Asiedu, Samuel Opoku
Kwarteng, Alexander
Amewu, Emmanuel Kobla Atsu
Kini, Priscilla
Aglomasa, Bill Clinton
Forkuor, John Boulard
author_facet Asiedu, Samuel Opoku
Kwarteng, Alexander
Amewu, Emmanuel Kobla Atsu
Kini, Priscilla
Aglomasa, Bill Clinton
Forkuor, John Boulard
author_sort Asiedu, Samuel Opoku
collection PubMed
description BACKGROUND: Human lymphatic filarial pathology is the leading cause of disability and poverty among people living with the infection. The second goal of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) is to manage the disease’s morbidity to improve patients’ quality of life. Consequently, the current study assessed the overall quality of life of lymphatic filariasis (LF) pathology patients in some selected endemic communities in rural Ghana. METHOD: In the present study, the Lymphatic Filariasis Quality of Life Questionnaire (LFSQQ) was used to evaluate the effect of lymphatic filariasis on the quality of life of people, with the disease in nine (9) communities in the Ahanta West District of the Western Region of Ghana where mass drug administration is being implemented for the past twenty years. Pearson’s correlation, linear regression, and one-way analysis of variance (ANOVA) analyses were used to assess the associations between the LFSQQ instrument domains. RESULTS: Of the 155 study participants recruited, 115 (74.19%) were females, and 40 (25.81%) males. A greater proportion of the study participants (40, 25.8%) were presented with stage two (2) lymphoedema, while only two patients had stage seven (7) lymphoedema. The average of the overall quality of life scores of study participants was 68.24. There was a negative Pearson correlation (r = − 0.504, p-value < 0.001) between the stage of lymphoedema (severity of the disease) and the quality of life of the LF patients. In addition, a clear pattern of positive correlation (r = 0.71, p-value < 0.001) was observed between the disease burden and pain/discomfort domains of the study participants. Whereas the highest domain-specific score (85.03) was observed in the domain of self-care, we noted that the environmental domain, which consists of the financial status, was the lowest (45.94) among the study participants. CONCLUSION: Our findings support previous works on the reduced quality of life among lymphatic filariasis patients with pathology. In this study, our results reveal a depressing financial condition among people presenting with late stages of LF pathologies, which eventually reduces their well-being.
format Online
Article
Text
id pubmed-7818560
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78185602021-01-22 Financial burden impact quality of life among lymphatic Filariasis patients Asiedu, Samuel Opoku Kwarteng, Alexander Amewu, Emmanuel Kobla Atsu Kini, Priscilla Aglomasa, Bill Clinton Forkuor, John Boulard BMC Public Health Research Article BACKGROUND: Human lymphatic filarial pathology is the leading cause of disability and poverty among people living with the infection. The second goal of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) is to manage the disease’s morbidity to improve patients’ quality of life. Consequently, the current study assessed the overall quality of life of lymphatic filariasis (LF) pathology patients in some selected endemic communities in rural Ghana. METHOD: In the present study, the Lymphatic Filariasis Quality of Life Questionnaire (LFSQQ) was used to evaluate the effect of lymphatic filariasis on the quality of life of people, with the disease in nine (9) communities in the Ahanta West District of the Western Region of Ghana where mass drug administration is being implemented for the past twenty years. Pearson’s correlation, linear regression, and one-way analysis of variance (ANOVA) analyses were used to assess the associations between the LFSQQ instrument domains. RESULTS: Of the 155 study participants recruited, 115 (74.19%) were females, and 40 (25.81%) males. A greater proportion of the study participants (40, 25.8%) were presented with stage two (2) lymphoedema, while only two patients had stage seven (7) lymphoedema. The average of the overall quality of life scores of study participants was 68.24. There was a negative Pearson correlation (r = − 0.504, p-value < 0.001) between the stage of lymphoedema (severity of the disease) and the quality of life of the LF patients. In addition, a clear pattern of positive correlation (r = 0.71, p-value < 0.001) was observed between the disease burden and pain/discomfort domains of the study participants. Whereas the highest domain-specific score (85.03) was observed in the domain of self-care, we noted that the environmental domain, which consists of the financial status, was the lowest (45.94) among the study participants. CONCLUSION: Our findings support previous works on the reduced quality of life among lymphatic filariasis patients with pathology. In this study, our results reveal a depressing financial condition among people presenting with late stages of LF pathologies, which eventually reduces their well-being. BioMed Central 2021-01-21 /pmc/articles/PMC7818560/ /pubmed/33478462 http://dx.doi.org/10.1186/s12889-021-10170-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Asiedu, Samuel Opoku
Kwarteng, Alexander
Amewu, Emmanuel Kobla Atsu
Kini, Priscilla
Aglomasa, Bill Clinton
Forkuor, John Boulard
Financial burden impact quality of life among lymphatic Filariasis patients
title Financial burden impact quality of life among lymphatic Filariasis patients
title_full Financial burden impact quality of life among lymphatic Filariasis patients
title_fullStr Financial burden impact quality of life among lymphatic Filariasis patients
title_full_unstemmed Financial burden impact quality of life among lymphatic Filariasis patients
title_short Financial burden impact quality of life among lymphatic Filariasis patients
title_sort financial burden impact quality of life among lymphatic filariasis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818560/
https://www.ncbi.nlm.nih.gov/pubmed/33478462
http://dx.doi.org/10.1186/s12889-021-10170-8
work_keys_str_mv AT asiedusamuelopoku financialburdenimpactqualityoflifeamonglymphaticfilariasispatients
AT kwartengalexander financialburdenimpactqualityoflifeamonglymphaticfilariasispatients
AT amewuemmanuelkoblaatsu financialburdenimpactqualityoflifeamonglymphaticfilariasispatients
AT kinipriscilla financialburdenimpactqualityoflifeamonglymphaticfilariasispatients
AT aglomasabillclinton financialburdenimpactqualityoflifeamonglymphaticfilariasispatients
AT forkuorjohnboulard financialburdenimpactqualityoflifeamonglymphaticfilariasispatients